Apr 15, 2010 · CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

Enhancing natural killer (NK) cell-based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the …

Cetuximab activated NK cells upregulate the costimulatory receptor CD137 (4-1BB) which, when triggered by agonistic mAb urelumab, might enhance NK cell functions, to promote T cell …

In this study, we evaluated the ability of 2 different glycoforms of a chimerized antihuman CD137 mAb, an aglycosylated (GA) and a low fucose form (GG), to react with human NK cells. Both …

Aug 1, 2019 · Expression of CD137 on NK cells is induced by the presence of cytokines (21, 22), and its engagement by CD137 ligand–positive aAPCs reinforce the activation of the MAPK …

Apr 15, 2010 · Here we report that human NK cells acquire expression of the TNFR family member CD137 upon activation, and NK cells of acute myeloid leukemia (AML) patients …

Oct 15, 2002 · By triggering NK-associated CD137 using either an agonistic mAb or CD137L-transfected cells, we show in this study that CD137 signaling stimulates proliferation and IFN-γ …

Dec 2, 2021 · Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming immunosuppression is an area of intensive research. Here, we have demonstrated that the …

Nov 19, 2014 · To clarify the mechanism for development of Epstein-Barr virus (EBV)-positive T- or NK-cell neoplasms, we focused on the costimulatory receptor CD137. We detected high …

Aug 1, 2008 · In this study, we evaluated the ability of 2 different glycoforms of a chimerized antihuman CD137 mAb, an aglycosylated (GA) and a low fucose form (GG), to react with …